Defective TFG-β signalling through the bone morphogen receptor type II is implicated in autosomal dominant and sporadic primary pulmonary hypertension. This fatal disorder is characterized by vascular remodelling, often triggered by the use of appetite-suppressant drugs which were, until recently, used to treat obesity.
This is a preview of subscription content, log in via an institution to check access.
References
Trembath, R.C. et al. Nature Genet. 26, 81– 84 (2000).
Nichols, W.C. et al. Nature Genet. 15, 277– 280 (1997).
Knowles, J.A. et al. Am. J. Hum. Genet. 67, 737– 744 (2000).
Nichols, W.C. et al. J. Med. Genet. (in press).
Massagué, J. & Chen, Y. Genes Dev. 14, 627–644 (2000).
Shovlin, C. J. Clin. Invest. 104, 1335–1336 (1999).
Lee, S.-D. J. Clin. Invest. 101, 927–934 (1998).
Lu, S.-L. Nature Genet. 19, 17–18 (1998).
Moore, L.G. N. Engl. J. Med. 333, 1248 (1995 ).
Aguirre, J.I. et al. Am. J. Physiol. 278, 981– 987 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, J. Pulling apart pulmonary hypertension. Nat Genet 26, 3–4 (2000). https://doi.org/10.1038/79148
Issue Date:
DOI: https://doi.org/10.1038/79148
- Springer Nature America, Inc.
This article is cited by
-
To be or not to BMP
Nature Genetics (2001)